Among these, we performed three primary comparisons (Supplementary File 1, Table 1) involving untreated, radiologically and clinically inactive MS cases (those without a gadolinium-enhancing or new lesion and without a clinical relapse within 6 months from the time of sample acquisition, referred to hereafter as “untreated and inactive MS”), with and without PRL, as well as cases with PRL despite treatment with anti-CD20-antibody-mediated B-cell depletion. The gene discussed is PRL; the disease is myeloid sarcoma.